266 related articles for article (PubMed ID: 32112040)
1. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Guo CH; Cao T; Zheng LT; Waddington JL; Zhen XC
Acta Pharmacol Sin; 2020 Apr; 41(4):499-507. PubMed ID: 32112040
[TBL] [Abstract][Full Text] [Related]
2. Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Xue B; Xiao W; Tian H
Biochem Biophys Res Commun; 2020 Jan; 521(1):245-251. PubMed ID: 31653343
[TBL] [Abstract][Full Text] [Related]
3. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
4. JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss.
Wang Q; He Q; Chen Y; Shao W; Yuan C; Wang Y
J Neuroinflammation; 2018 Jun; 15(1):184. PubMed ID: 29907159
[TBL] [Abstract][Full Text] [Related]
5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
6. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.
Ren ZX; Zhao YF; Cao T; Zhen XC
Acta Pharmacol Sin; 2016 Sep; 37(10):1315-1324. PubMed ID: 27374489
[TBL] [Abstract][Full Text] [Related]
7. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
[TBL] [Abstract][Full Text] [Related]
8. Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Haga H; Yamada R; Izumi H; Shinoda Y; Kawahata I; Miyachi H; Fukunaga K
Pharmacol Biochem Behav; 2020 Apr; 191():172891. PubMed ID: 32126223
[TBL] [Abstract][Full Text] [Related]
9. Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease.
Voronin MV; Kadnikov IA; Voronkov DN; Seredenin SB
Sci Rep; 2019 Nov; 9(1):17020. PubMed ID: 31745133
[TBL] [Abstract][Full Text] [Related]
10. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Costantini LC; Cole D; Chaturvedi P; Isacson O
Eur J Neurosci; 2001 Mar; 13(6):1085-92. PubMed ID: 11285005
[TBL] [Abstract][Full Text] [Related]
11. Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
Spathis AD; Asvos X; Ziavra D; Karampelas T; Topouzis S; Cournia Z; Qing X; Alexakos P; Smits LM; Dalla C; Rideout HJ; Schwamborn JC; Tamvakopoulos C; Fokas D; Vassilatis DK
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3999-4004. PubMed ID: 28348207
[TBL] [Abstract][Full Text] [Related]
12. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
13. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
[TBL] [Abstract][Full Text] [Related]
14. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
15. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
16. Dicer and microRNAs protect adult dopamine neurons.
Chmielarz P; Konovalova J; Najam SS; Alter H; Piepponen TP; Erfle H; Sonntag KC; Schütz G; Vinnikov IA; Domanskyi A
Cell Death Dis; 2017 May; 8(5):e2813. PubMed ID: 28542144
[TBL] [Abstract][Full Text] [Related]
17. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
[TBL] [Abstract][Full Text] [Related]
18. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
19. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
20. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
